Isareli diagnostics company developing blood-based CRC test — 4 insights

Todos Medical wants to follow in the competition's footsteps in developing and promoting its blood-based colorectal cancer test, CEO Herman Weiss, MD, said in an update on the state of the company at a conference in Los Angeles.

What you should know:

1. Todos is developing TM-C1, a blood-based diagnostic test for colon cancer.

2. Todos is in the midst of studying TM-C1.

3. When elaborating on the next steps for TM-C1, Dr. Weiss referenced Exact Sciences' developmental path.

"Exact Sciences has shown successful adoption for their colon cancer stool test and we believe we can replicate their roadmap to success with a simple blood test," Dr. Weiss said.

4. The company has blood-based tests for breast and other cancers in development.

More articles on gastroenterology::
Pennsylvania's $12.5M tax on ASCs could cause dozens to close, lawmaker says — 5 key points
Novant Health makes $1.8B impact with network of outpatient facilities, medical centers
Vermont Gov. signs ASC licensure bill into law — 5 key details

© Copyright ASC COMMUNICATIONS 2021. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Featured Webinars

Featured Whitepapers